South Asia Journal Watch: 18 November 2026

South Asia Journal Watch

South Asia Journal Watch

South Asia Journal Watch: 18 November 2026

Microbiology, infectious disease, AMR and infection-control papers from India and South Asia added to PubMed on 16 to 18 November 2026 and not covered in earlier issues.

Lead articles

Virology · Outbreak surveillance · New Microbes and New Infections

Measles resurgence in Bangladesh in 2026: national surveillance trends, cumulative divisional burden, and historical vaccination context

New Microbes and New Infections · doi:10.1016/j.nmni.2026.101883 · PubMed 43041790

What
A descriptive analysis of the early phase of the 2026 measles resurgence in Bangladesh, set against national surveillance data and historical vaccination coverage.
Design
Analysis of Directorate General of Health Services (DGHS) bulletins dated 2-30 April 2026, reporting cumulative totals from 15 March. Division-level cumulative counts were reconstructed from the 22 April bulletin and population-standardised notification rates were calculated using the 2022 census. Official national measles-containing vaccine (MCV) coverage for 2019, 2023 and 2024 provided historical context.
Key findings
By 30 April, DGHS reported 37,131 suspected and 5028 confirmed cases, with 227 suspected and 49 confirmed deaths. On 22 April, cumulative division-level totals were 27,164 suspected and 3934 confirmed cases. Dhaka recorded 2634 confirmed cases, or 5.957 per 100,000 population. Official national MCV1 and MCV2 coverage in 2024 was 86.1% and 80.7%, respectively.
Limitations
Descriptive analysis of bulletin data covering roughly six weeks. Earlier division-level childhood MR1 measurements were not contemporaneous with the outbreak and were not used for correlation testing; the authors caution against causal inferences from historical aggregate coverage.
Relevance to South Asia
The authors describe substantial reported burden and geographic heterogeneity, and call for matched reporting windows and stronger age- and vaccination-status surveillance.

Malaria · Drug resistance · PLOS ONE

Molecular surveillance of resistance mutations in Plasmodium vivax clinical samples from southwestern India

PLOS ONE · doi:10.1371/journal.pone.0362585 · PubMed 43043926

What
Molecular surveillance of drug-resistance markers in Plasmodium vivax clinical samples from southwestern India, where chloroquine followed by 14-day primaquine is the recommended treatment.
Design
93 P. vivax samples from symptomatic adults at three sites in two districts: Kasturba Medical College, Manipal (July 2021 to September 2024), Udupi District Hospital and the Malaria Clinic, Mangaluru District Hospital (both July 2022 to September 2024). Pvcrt-o, Pvmdr1, Pvdhfr and Pvdhps were sequenced by the Sanger method and haplotypes analysed.
Key findings
The Pvcrt-o K10 AAG insertion was detected in 26% of samples. Pvmdr1 M908L, T958M, Y976F and F1076L mutations were present in 100%, 86.02%, 2.15% and 84.94% of samples, respectively. Pvdhps A383G and A553G were found in 26.88% and 13.97%, and Pvdhfr S58R and S117N in 59.13% and 56.98%, with the S58R+S117N double mutant the most prevalent haplotype.
Limitations
Marker-based study of 93 samples from one region, without phenotypic susceptibility testing reported in the abstract. The authors state that the mutations do not indicate complete chloroquine resistance.
Relevance to South Asia
The Y976F mutation, seen in two samples, has previously been associated with reduced chloroquine susceptibility. The authors call for ongoing molecular surveillance in India.

More from the journals

Antimicrobial resistance

Tuberculosis and mycobacteria

Vector-borne and parasitic

Infection prevention and HAI

Enteric infections

Virology

Respiratory and paediatric

Items are summaries of published abstracts and are not clinical advice. Readers should consult the original article. Figures are quoted as reported in each abstract.

Leave a Reply

Your email address will not be published. Required fields are marked *